Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FMX114
- Development stage
- Discontinued
- Lead developer
- Vyne Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
FMX114 is a proprietary investigational topical combination gel developed by Vyne Therapeutics for the treatment of mild-to-moderate atopic dermatitis. It combines two small molecule drugs— tofacitinib, a Janus kinase (JAK) inhibitor, and fingolimod, a sphingosine 1-phosphate receptor modulator. Tofacitinib acts intracellularly to reduce inflammation by inhibiting cytokine release from inflammatory cells via JAK1 and JAK2 inhibition. Fingolimod acts extracellularly as an S1P1 modulator to inhibit migration of inflammatory cells and may also support skin barrier recovery by upregulating filaggrin expression. The formulation is designed to concentrate anti-inflammatory effects in the skin while minimizing systemic exposure. FMX114 has been evaluated in Phase 1b/2a clinical trials for atopic dermatitis but did not meet its primary efficacy endpoints in Phase 2a[1][4][5][6][7].
- Brand names
- FMX114FMX-114FMX 114
- Other names
- tofacitinib + fingolimod topical gel
02
Targets
JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)JAK3 (Janus kinase 3)S1PR3 (Sphingosine 1-phosphate receptor 3)S1PR4S1PR5 (Sphingosine-1-phosphate receptor 5)EDG1 (Sphingosine-1-phosphate receptors)
Beyond the preview
Go deeper on FMX114.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FMX114.